Alma TED Transepidermal Drug Delivery Hair Restoration Explained: The Two-Stage Ultrasound Protocol That Gets Serums Past the Skin Barrier Without a Single Needle

Introduction: Why 80 Million Americans Are Still Losing the Battle Against Hair Loss

More than 80 million men and women in the United States experience some form of hair loss, according to the American Hair Loss Association. If that number feels staggering, it should. Hair loss is one of the most widely shared human experiences, and yet, for decades, the tools available to treat it have run into the same stubborn wall.

That wall is literal. It is the skin’s own outermost barrier, the stratum corneum, and it has quietly sabotaged countless topical serums and minoxidil applications by blocking active ingredients before they ever reach the follicle. A patient can apply a perfectly good compound to the scalp every day and still see only marginal results, simply because most of that compound never gets past the surface.

Alma TED was designed to solve exactly this problem. It is a non-invasive, needle-free technology that uses acoustic sound waves to temporarily open the skin barrier and drive hair-growth compounds directly to where they are needed. No incisions. No injections. No anesthesia.

This article explains the actual physics behind the two-stage Alma TED protocol in plain language, distinguishes FDA clearance from FDA drug approval, and offers an honest assessment of what the current evidence does and does not show. Charles Medical Group, a South Florida hair restoration practice with over 25 years of exclusive focus on the field, offers Alma TED as part of a broader commitment to education-first, honest patient care. That means no glossing over evidence limitations. Informed patients make better decisions, and better decisions lead to better outcomes.

The Real Obstacle: Understanding the Stratum Corneum Barrier

The stratum corneum is the outermost layer of the epidermis and the body’s primary physical and chemical shield against the outside world. It keeps water in and pathogens out, and it does its job remarkably well.

The best way to picture it is as a brick wall. The corneocytes (dead, flattened skin cells) act as the bricks. Holding them together is a mortar made of tightly packed lipid bilayers composed of ceramides, cholesterol, and fatty acids. This architecture is brilliant for protection. Unfortunately, it is equally brilliant at frustrating drug delivery.

Most therapeutic molecules, including the peptides and growth factors that support hair health, are simply too large or too water-loving to slip through that lipid mortar on their own. As a review published in Molecular Pharmaceutics notes, topical administration is the main treatment strategy for hair loss, yet the skin barrier remains the central challenge hindering drug penetration. The same review points out that roughly 50% of men and 15 to 30% of women worldwide experience hair loss, making this a barrier that affects an enormous population.

This is precisely why standard topical minoxidil achieves only partial penetration, and why the follicle, which sits deep in the dermis, is so often underserved by surface-applied treatments. The logic is unavoidable: if the barrier is the problem, any effective solution has to address the barrier first. That is exactly what Alma TED’s two-stage protocol is built to do.

What Is Alma TED? A Plain-Language Overview

TED stands for TransEpidermal Delivery, which describes the controlled movement of therapeutic compounds across the skin rather than through a puncture in it. The distinction matters and becomes clearer as the mechanism is explained.

The technology was developed by Alma Lasers, now part of Sisram Medical, and introduced to the U.S. market in 2022. At a hardware level, Alma TED is a handheld ultrasound device operating in the low-frequency range of 20 to 40 kHz, paired with a patented air pressure delivery system called the Impact Delivery tip.

It is equally important to be clear about what Alma TED is not. It involves no needles, no incisions, no blood draws, no anesthesia, and no downtime. That immediately sets it apart from procedures like PRP and microneedling.

The device works alongside a companion serum, the TED+ Hair Care Formula, which contains peptides, growth factors, and amino acids formulated specifically for delivery through this mechanism. The technology is protected under US Patent No. US 10,238,849 B2, which documents its proprietary approach.

The real story, however, is in the physics, which the following sections unpack in detail.

The Physics Behind the Protocol: Acoustic Cavitation and Sonophoresis Explained

This is the scientific core of the treatment, the part most competitor content skips. Alma TED is powered by two well-established physical phenomena: acoustic cavitation and sonophoresis (also called phonophoresis). Both are supported by decades of peer-reviewed research and at least 150 independent scientific reports.

Acoustic Cavitation: Creating Temporary Microchannels Without Breaking the Skin

Acoustic cavitation occurs when low-frequency ultrasound waves pass through a liquid medium (the coupling gel or serum on the scalp) and create rapid cycles of pressure that generate microscopic gaseous bubbles.

There are two types. In stable cavitation, the bubbles oscillate without collapsing. In inertial (or transient) cavitation, the bubbles collapse violently, producing micro-jets and shock waves. These forces structurally modify the lipid bilayers of the stratum corneum, creating temporary aqueous pathways, or microchannels, through which larger molecules can travel.

As a review in the International Journal of Nanomedicine explains, “the mechanical effects of acoustic cavitation play a significant role in increasing skin permeability; shock waves are hypothesized to structurally modify stratum corneum lipids to produce diffusion channels.” A separate PubMed study reinforces the point, finding that calcein permeability during ultrasound application correlated well with cavitation generation, underscoring the role of cavitation collapse in solute penetration and skin permeabilization.

Crucially, these microchannels are temporary. The skin’s natural barrier function restores itself within hours, so no lasting alteration to the scalp occurs. The low frequency matters here as well: lower frequencies generate more aggressive cavitation closer to the skin surface, making them far more effective for transdermal delivery than the high-frequency ultrasound used in diagnostic imaging.

Sonophoresis: Using Sound Waves to Drive Compounds Deep Into the Scalp

Sonophoresis is the use of ultrasound energy to enhance the penetration of topically applied substances through the skin. Beyond cavitation, it works through several mechanisms: acoustic streaming (directional fluid movement driven by ultrasound), mild thermal effects that increase membrane fluidity, and convective transport through hair follicles and sweat ducts.

A 2024 review in Advances in Pharmacological and Pharmaceutical Sciences explains that “cavitation bubble oscillation causes convective transport through the skin, hair follicles, and sweat ducts, making low-frequency sonophoresis particularly advantageous for drug delivery.” This is significant because hair follicles themselves act as preferential pathways, or shunt routes, for sonophoresis-enhanced delivery, making the scalp an especially favorable target.

The evidence base here is not experimental. A landmark 2020 study in Scientific Reports found that dual-frequency ultrasound-mediated microbubble cavitation enhanced minoxidil delivery so effectively that pigskin penetration depth was 2.86 times greater than in the control group, with increased hair growth efficacy. A 2025 review in Pharmaceutics further identifies ultrasound-based delivery as a key emerging technology for androgenetic alopecia, placing it alongside microneedles, liposomes, and nanostructured lipid carriers.

The Two-Stage Alma TED Protocol: What Actually Happens During a Session

Here the physics translates into the patient experience. Each session lasts roughly 25 to 35 minutes with zero downtime.

Stage 1: The Priming Pass

In Stage 1, the ultrasound handpiece glides methodically across the scalp in a priming pass, delivering low-frequency acoustic energy to the treatment area. The physiological goal is straightforward: acoustic cavitation disrupts the lipid bilayers of the stratum corneum, creating the temporary microchannels described above.

Most patients describe the sensation as a warm, vibrating feeling similar to a scalp massage. There is no pain and no anesthesia required. Some patients may notice a brief, mild ringing in the ears because ultrasound waves can conduct through bone. This is transient and resolves immediately once the handpiece moves away.

The priming concept is essential. Stage 1 does not deliver the therapeutic serum; it prepares the skin to receive it. The sequence matters because the barrier must be disrupted before delivery begins. At the end of this pass, the skin sits in a state of temporarily enhanced permeability, a window of opportunity that Stage 2 is built to exploit.

Stage 2: The Delivery Pass

In Stage 2, the TED+ Hair Care Formula is applied to the scalp, and the handpiece (now using the Impact Delivery air pressure tip) drives the peptides, growth factors, and amino acids through the temporarily permeable skin.

The mechanism here is sonophoresis in action: acoustic streaming, convective transport, and continued cavitation actively push the serum molecules through the microchannels and along follicular shunt routes toward the dermal papilla. The TED+ formula is not a generic topical; it is engineered with molecular sizes and properties optimized for ultrasound-assisted transdermal delivery. The Impact Delivery tip contributes a pneumatic assist, using air pressure to help propel the serum into the skin alongside the acoustic energy.

The sensation remains comfortable throughout, warm and vibrating, with no needles or skin puncture at any point. Afterward, patients can resume normal activities immediately and wash their hair after a few hours.

In short: Stage 1 opens the door; Stage 2 walks the serum through it. The sequence is not interchangeable.

FDA Clearance vs. FDA Approval: An Important Distinction Every Patient Should Understand

This is one of the most frequently misrepresented aspects of Alma TED in marketing content, and patients deserve a clear explanation.

FDA clearance happens through the 510(k) pathway. A manufacturer submits evidence that a new device is “substantially equivalent” in safety and intended use to a legally marketed predicate device. The FDA reviews that evidence and, if satisfied, clears the device for marketing. Alma TED is FDA-cleared as a Class II medical device for androgenetic alopecia (male and female pattern hair loss) via this pathway.

FDA clearance means the device has been reviewed for safety and substantial equivalence. It is a legitimate regulatory milestone that allows the device to be legally marketed and used in clinical settings.

What FDA clearance does not mean is full FDA drug approval. Drug approval follows the PMA or NDA pathway and requires large-scale randomized controlled trials demonstrating efficacy. The 510(k) pathway does not demand that same depth of clinical evidence.

For patients, this distinction matters. Alma TED is a legitimate, regulated medical device, but “510(k) cleared” should not be read as equivalent to the evidence base behind FDA-approved drugs like minoxidil or finasteride. Understanding this distinction is not a knock against the technology; it is how patients calibrate expectations appropriately. Charles Medical Group holds that informed patients are better patients, and that honest communication about regulatory nuance is part of responsible medical practice.

What Does the Evidence Actually Show? An Honest Assessment

This is the evidence review most competitor content avoids.

On the positive side, a manufacturer-sponsored clinical study of 50 patients reported that after three treatments, 98% experienced reduced shedding, 96% noted increased hair growth, 89% observed visible improvement in density, and 100% expressed high satisfaction. Separately, a single-center study by Dy et al. of 31 patients (29 females, 2 males) found a 23% increase in hair density at one month and 31% at six months, with no pain or adverse events reported.

The limitations deserve equal candor. As of 2026, large-scale independent randomized controlled trials for Alma TED specifically remain limited. Existing studies are largely manufacturer-sponsored and small-scale, and long-term data beyond six months is not yet robust. This is normal for a newer technology. The absence of large RCTs does not mean the technology does not work; it means the device-specific evidence base is still maturing.

What supports cautious optimism is the underlying science. Sonophoresis is validated by decades of independent research and at least 150 peer-reviewed reports. The 2020 Scientific Reports study and the 2025 Pharmaceutics review both reinforce the mechanism. The American Hair Loss Association also recognizes TED as a non-invasive treatment option, referencing a Journal of Drugs in Dermatology study on TED-enhanced minoxidil penetration.

The honest bottom line: the mechanism is scientifically credible, early results are promising, and the safety profile is excellent. Alma TED is best approached as a well-grounded emerging therapy rather than a fully proven treatment with decades of large-scale trial data behind it.

Who Is and Is Not a Good Candidate for Alma TED

Honesty about who benefits and who does not builds more trust than promotional messaging ever could.

Ideal Candidates: Where Alma TED Performs Best

• Early-to-moderate androgenetic alopecia (male and female pattern hair loss), the primary FDA-cleared indication.
• Diffuse thinning across the scalp where follicles are still present but miniaturized.
• Postpartum hair shedding (telogen effluvium triggered by hormonal changes after childbirth).
• Stress-related telogen effluvium, the temporary shedding triggered by physical or emotional stress.
• Hormonal hair changes, such as perimenopausal thinning.
• Needle-averse patients (trypanophobia) who decline or cannot undergo PRP, microneedling, or surgery. Alma TED eliminates every needle touchpoint: no blood draw, no centrifugation, no scalp injections.
• Patients seeking a comfortable, zero-downtime maintenance protocol to complement other treatments.
• Post-hair transplant patients looking to support graft survival and optimize scalp health during recovery.

Who Is Not a Good Candidate: Important Limitations

• Patients with advanced baldness and complete follicular destruction. Alma TED can only support and enhance existing follicles. If the follicle is permanently gone, no amount of serum delivery will restore it.
• Scarring alopecia (such as lichen planopilaris or frontal fibrosing alopecia), where follicles are destroyed through scarring.
• Active scalp infections, open wounds, or inflammatory scalp conditions in the treatment area.
• Patients with certain implanted electronic devices such as pacemakers, since ultrasound devices carry standard contraindications to review during consultation.
• Patients expecting surgical-level density restoration. Alma TED is a supportive therapy, not a replacement for transplant surgery in significant hair loss.

A thorough consultation with a qualified hair restoration physician is essential to determine candidacy. Self-assessment is not sufficient.

The Treatment Timeline: What to Expect and When

The standard protocol involves three sessions spaced four to six weeks apart, followed by a maintenance session at approximately six months.

Results follow their own honest timeline. Reduced shedding is typically noticed at weeks four to six after the first session. New growth becomes visible around months two to three. The best results are generally observed at the six-month mark. The reason for the wait is biology: hair grows in cycles (anagen, catagen, telogen), so even when follicles are stimulated, new terminal hairs take months to emerge and thicken visibly.

Alma TED is not a one-time cure. Because the stratum corneum disruption is temporary, ongoing sessions are needed to maintain enhanced serum delivery and sustained follicular stimulation. This is not unique to Alma TED. All non-surgical hair loss treatments, including minoxidil, PRP, and low-level laser therapy, require ongoing use because androgenetic alopecia is a progressive, chronic condition.

Each session takes roughly 25 to 35 minutes with zero downtime. Patients resume normal activities immediately and wash their hair after a few hours.

Alma TED vs. PRP and Microneedling: How the Delivery Mechanisms Compare

This is a mechanism comparison, not a verdict. All three have legitimate roles, and the right choice depends on individual factors.

PRP (Platelet-Rich Plasma) requires a blood draw, centrifugation to concentrate platelets, and direct scalp injections. Variability in preparation protocols affects outcomes. A 2025 meta-analysis of 43 RCTs confirmed PRP efficacy with moderate-quality evidence. However, every step involves needles, which makes it unsuitable for patients with trypanophobia.

Microneedling uses fine needles to create micro-punctures that enhance serum penetration. It is effective but involves skin puncture, potential discomfort, and a brief recovery period with possible redness or sensitivity.

Alma TED achieves comparable enhanced serum delivery without any skin puncture, blood draw, or injection. The microchannels are created acoustically, not mechanically. That is a meaningful clinical differentiator.

There is a nuance worth noting: delivering PRP via Alma TED is less validated because platelets are relatively large particles. CRP (Cytokine-Rich Plasma, growth factors under 3 micrometres) is being explored for Alma TED delivery, though it requires further study before it can be considered a validated protocol.

For needle-averse patients, the key point is straightforward: Alma TED is the only mechanism in this comparison that achieves transdermal delivery without a single needle touchpoint, making it a clinically legitimate choice, not merely a convenient one. It can also be combined with other modalities such as LLLT, topical minoxidil, oral finasteride, and post-transplant protocols for a comprehensive approach.

Alma TED in the Broader Hair Restoration Landscape

The global hair restoration services market is valued at approximately USD 8.19 billion in 2026, growing at a CAGR of 8.84%, according to Mordor Intelligence. Non-surgical therapies now represent roughly 44% of the total market and are driving much of that growth.

That shift reflects genuine changes in patient preference toward less invasive, lower-downtime options that fit into ongoing wellness routines. Alma TED sits squarely in this movement, representing the convergence of well-validated sonophoresis science with modern device engineering, arriving precisely when demand for needle-free options is at an all-time high.

The 2025 Pharmaceutics review frames ultrasound-based delivery as a key emerging technology for androgenetic alopecia, situating Alma TED within a broader scientific trajectory rather than as an isolated novelty. Looking forward, the exploration of CRP for delivery via Alma TED may represent a next frontier, though further research is needed before any combined protocol can be considered validated.

None of this changes a core truth: surgical hair restoration such as FUE and FUT remains the gold standard for significant hair loss. Alma TED is a complement to, not a replacement for, surgical options in appropriate cases.

Why Charles Medical Group Offers Alma TED: The Philosophy Behind the Technology

For more than 25 years, Charles Medical Group has focused exclusively on hair restoration, treating it as both a medical discipline and an art form. Alma TED fits naturally within that philosophy.

Dr. Glenn Charles evaluates new technologies against a rigorous standard of scientific credibility and patient benefit. As a Past President of the American Board of Hair Restoration Surgery, a Fellow of the ISHRS, and the author and editor of the field’s most widely recognized textbooks, he does not adopt technology casually. Alma TED earned its place alongside the practice’s full spectrum of evidence-based options, from surgical solutions like FUE, FUT, and ARTAS robotic restoration to non-surgical approaches including LLLT and medical therapy.

The practice also recognizes that trypanophobia is a legitimate clinical consideration, not a preference to be dismissed. For patients who would otherwise forgo treatment entirely, Alma TED provides a scientifically grounded, needle-free pathway.

That same transparency extends to how Alma TED is presented: with clear acknowledgment of what the evidence shows and what it does not yet show. Virtual consultations via FaceTime and Skype are available for patients outside the Boca Raton and Brickell, Miami areas, and the practice serves patients across Palm Beach, Fort Lauderdale, and Orlando.

Conclusion: The Science Is Real, and So Are the Limitations

Alma TED uses low-frequency ultrasound to trigger acoustic cavitation, temporarily disrupting the stratum corneum’s lipid barrier, and sonophoresis, driving therapeutic compounds through the resulting microchannels, in a precise two-stage protocol. Stage 1 (the priming pass) opens the barrier. Stage 2 (the delivery pass) exploits that window to deliver the TED+ serum toward the follicle. The sequence is deliberate and grounded in physics.

The evidence picture is equally clear. The mechanism is supported by decades of independent sonophoresis research. Early Alma TED-specific studies are promising but small-scale and largely manufacturer-sponsored, and large-scale independent RCTs are still needed. On the regulatory side, FDA clearance via the 510(k) pathway is a legitimate milestone, but it is not the same as full FDA drug approval, and patients should understand the difference.

For the right patient, especially those with early-to-moderate androgenetic alopecia, diffuse thinning, or shedding conditions, and above all those who are needle-averse, Alma TED offers a scientifically credible, comfortable, and well-tolerated option worth serious consideration.

Understanding the science behind a treatment is not merely intellectual curiosity. It is how patients become active participants in their own care, ask sharper questions, and make decisions they can feel genuinely confident about.

Ready to Find Out If Alma TED Is Right for You? Schedule a Consultation with Charles Medical Group

The best next step is a complimentary, no-pressure consultation with Dr. Glenn Charles to evaluate a specific hair loss pattern and determine whether Alma TED, a combination protocol, or another approach makes the most sense.

Dr. Charles personally meets with each patient, reviews their history, and develops a custom treatment plan. In-person consultations are available at the Boca Raton and Brickell (Miami) locations, and virtual consultations via FaceTime and Skype are open to patients in Palm Beach, Fort Lauderdale, Orlando, and beyond.

To schedule, call 866-395-5544 or visit charlesmedicalgroup.com.

The goal of the consultation is information and clarity. Patients leave with a clear understanding of their options and realistic expectations, with no obligation. At Charles Medical Group, the science matters, and so does the patient living with hair loss.